Coeptis Therapeutics, Inc.

NASDAQ:COEP

Biotechnology

Healthcare
$14.64 +4.68%

+$0.73 today

Market cap
$57.63M
Beta
-0.43
P/E (TTM)
-8.3
EPS (TTM)
-$1.97
52W Low $6.80High $21.41

Volume 0.18M

Average 0.05M

COEP Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Coeptis Therapeutics, Inc.NASDAQ: COEP

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses dips below year-ago levels

Q1 FY2026 operating expenses of $3.98M fell 2.2% year over year, behind the +26.1% change in trailing-twelve-month operating expenses. Sequentially, it rose 42.0% from the prior quarter. Over 3 fiscal years it compounded at -25.3% a year.

Context

  • Operating expenses amounted to 1043.7% of revenue in FY2025.
  • Operating expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -2.2% toward the trailing-twelve-month pace of +26.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.98M+42.0% QoQ
Last fiscal yearDec 2025
$14.23M+41.5% YoY
LTMMar 2026
$14.13M+26.1% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.2%——
1 year+41.5%——
3-year CAGR-25.3%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
14.23M USD
Year-over-year change
+41.5%
4-year CAGR
+0.2%

Operating Expenses vs competitors

How COEP compares with its peers on the latest reported figures

  • COEP's LTM Mar 2026 operating expenses of $14.13M is the 8th highest of the 9 companies compared; the peer median is $42.87M.
  • Its year-over-year change of +26.1% is the 2nd highest of 9, against a peer median of -16.3%.
  • Operating expenses amounts to 999.7% of revenue for COEP, versus a peer median of 473.2%.
COEP Competitors Peer median
Operating Expenses for COEP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$229.32M -10.3%-7.8%151.8%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$87.08M -41.0%-7.2%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$59.37M -22.3%+2.5%17821.9%
CUECue Biopharma, Inc.LTM Mar 2026$52.24M +6.3%-0.3%159.6%
OSTXOS Therapies IncorporatedLTM Mar 2026$33.51M +199.7%+85.4%—
EQEquillium, Inc.LTM Mar 2026$20.3M -54.6%-32.8%—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$18.04M +2.8%-27.4%786.8%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$14.13M +26.1%-25.3%999.7%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$9.39M -25.3%+131.1%—
Peer median (excluding COEP) $42.87M-16.3%-3.7%473.2%

Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75K0001.36M
Cost of Revenue0000180.63K
Gross Profit75K0001.18M
Gross Margin100.0%———86.7%
Research & Development020.89K6.67M2.33M1.28M
Selling, General & Admin14.12M34.18M13.82M6.72M11.95M
Operating Expenses14.12M34.2M21.49M10.05M14.23M
Depreciation & Amortization447.41K1M1.04M1.04M1.22M
EBITDA(12.81M)(36.35M)(20.12M)(9.38M)(10.41M)
EBITDA Margin-17086.3%———-763.9%
Operating Income(14.05M)(34.2M)(21.49M)(10.05M)(13.04M)
Operating Margin-18727.9%———-956.9%
Interest Income0000116.5K
Interest Expense187.13K218.41K107.69K396.12K642.38K
Other Income / Expenses596.65K(3.38M)224.59K(822.92K)766.31K
Income Before Tax(13.45M)(37.57M)(21.27M)(10.88M)(12.28M)
Pre-Tax Margin-17932.4%———-900.7%
Income Tax Expense00000
Net Income(13.45M)(37.57M)(21.27M)(10.68M)(11.92M)
Net Margin-17932.4%———-874.3%
EPS (Basic)(13.16)(2.87)(0.83)(5.65)(2.81)
EPS (Diluted)(13.16)(2.87)(0.83)(5.65)(2.81)
Weighted Avg Shares1.02M14.3M25.69M1.93M4.23M
Weighted Avg Shares (Diluted)1.02M14.3M25.69M1.93M4.23M

Coeptis Therapeutics, Inc.

NASDAQ:COEP

Intrinsic Alpha fair value

Locked

Current Price

$14.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.